These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30417774)

  • 21. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research progress of coumarins and their derivatives in the treatment of diabetes.
    Pan Y; Liu T; Wang X; Sun J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):616-628. PubMed ID: 35067136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidiabetic drugs of plant origin used in China: compositions, pharmacology, and hypoglycemic mechanisms.
    Jia W; Gao WY; Xiao PG
    Zhongguo Zhong Yao Za Zhi; 2003 Feb; 28(2):108-13. PubMed ID: 15015278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacology of oral antidiabetic agents (first of two parts).
    Shen SW; Bressler R
    N Engl J Med; 1977 Mar; 296(9):493-7. PubMed ID: 319363
    [No Abstract]   [Full Text] [Related]  

  • 25. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
    Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
    Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecules from natural sources, targeting signaling pathways in diabetes.
    Liu Q; Chen L; Hu L; Guo Y; Shen X
    Biochim Biophys Acta; 2010; 1799(10-12):854-65. PubMed ID: 20601278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Starch synthase IIIa and starch branching enzyme IIb-deficient mutant rice line ameliorates pancreatic insulin secretion in rats: screening and evaluating mutant rice lines with antidiabetic functionalities.
    Tanaka Y; Takahashi K; Kato JI; Sawazaki A; Akasaka T; Fujita N; Kumamaru T; Saito Y; Shirouchi B; Sato M
    Br J Nutr; 2018 May; 119(9):970-980. PubMed ID: 29532765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.
    McBrayer DN; Tal-Gan Y
    Drug Dev Res; 2017 Sep; 78(6):292-299. PubMed ID: 28786125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advancements in the anti-diabetes chemotherapeutics based on amino acids, peptides, and peptidomimetics.
    Jain R; Chawrai S
    Mini Rev Med Chem; 2005 May; 5(5):469-77. PubMed ID: 15892688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update.
    Al Kury LT; Abdoh A; Ikbariah K; Sadek B; Mahgoub M
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of newer concepts in diabetes.
    Fineberg SK
    J Am Geriatr Soc; 1966 May; 14(5):463-71. PubMed ID: 9752382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.
    Tsai SF; Chen CH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Insulin secretion and sensitivity in patients with secondary failure to oral hypoglycemic drugs].
    López G; Calvillán M; Durruty P; Rocha G
    Rev Med Chil; 1992 Sep; 120(9):969-77. PubMed ID: 1340989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current status and issues of clinical development of novel anti-diabetic drugs].
    Kimura T; Kaku K
    Nihon Rinsho; 2013 Nov; 71(11):2030-7. PubMed ID: 24397179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of insulin and oral antidiabetic drugs in renal insufficiency.
    Hasselblatt A
    Contrib Nephrol; 1989; 73():139-45; discussion 146. PubMed ID: 2689089
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of antidiabetic sulfanilamide preparations].
    Genes SG
    Ter Arkh; 1970 Jan; 42(1):15-21. PubMed ID: 5446836
    [No Abstract]   [Full Text] [Related]  

  • 37. [Insulin response and lipid and purine metabolic disorders in protodiabetes: evaluation of the changes induced with hypoglycemic drug treatment].
    Baraldi B; Carobbio C; Colloredo Mels G; Cocuzza E; Maestri G; D'Amore V; Angeli G
    Clin Ter; 1980 Apr; 93(2):193-202. PubMed ID: 7004754
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus.
    Gouni-Berthold I; Hanssen R; Ravarani L; Berthold HK
    Curr Pharm Des; 2017; 23(31):4573-4582. PubMed ID: 28911306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oral antidiabetic agents].
    Vonesch HJ
    Schweiz Rundsch Med Prax; 1988 Mar; 77(9):210-2. PubMed ID: 3283906
    [No Abstract]   [Full Text] [Related]  

  • 40. Physiological regulation of the pancreatic {beta}-cell: functional insights for understanding and therapy of diabetes.
    McClenaghan NH
    Exp Physiol; 2007 May; 92(3):481-96. PubMed ID: 17272356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.